Answers are grounded in this paper and cite their sources.
The Panel noted that the additional phenylalanine intake expected from ingestion of neotame as a general purpose sweetener represents a relatively small increment in the exposure to of the phenylketonuric homozygous child. hypothetical formation of nitrosamines in the gastrointestinal tract from reaction of nitrite with neotame and its major degradation product and/or metabolite NC-00751 has been by the Panel. No nitrosated neotame (N-nitroso-(3,3-dimethyl)-L-aspartyl-Lphenylalanine methyl ester, N-nitrosoneotame; NC-00799) and no nitrosated de-esterified (N-nitroso-(3,3-dimethylbuthyl)-L-aspartyl-L-phenylalanine, NC- 00800) could be detected under simulated gastric juice conditions. Furthermore, both compounds were and shown to be without mutagenic activity in the Ames test. In view of the high sensitivity of the Ames test to genotoxic nitrosocompounds, the Panel considered that of neotame, should it occur, is not a matter of safety concern. After considering all the data on stability, degradation products and toxicology, the Panel concluded that neotame is not of safety concern with respect to the proposed uses as a Panel established an Acceptable Daily Intake (ADI) of 0-2 mg/kg bw/day based on the application of a 100-fold safety factor to the NOAEL of 200 mg/kg bw from a 52-week dog. estimates of dietary exposure both in adults and children suggest that it is very unlikely that the ADI would be exceeded at the proposed use levels.
No takes yet. Share an insight, caveat, or question.
A 2007 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: